Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Spagnolo

Showing results (81-90 of 116) with videos related to

Pageof 12
Sort By:
The Lancet. Oncology|July 17, 2023
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 studyReinhard Dummer, Paola Queirolo, Pauline Gerard Duhard, et al.
The Lancet. Oncology|August 8, 2022
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 studyReinhard Dummer, Paola Queirolo, Ana Maria Abajo Guijarro, et al.
International Journal of Molecular Sciences|March 11, 2023
Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World SettingIrene Vanni, Lorenza Pastorino, Enrica Teresa Tanda, et al.
Journal of Neuro-Oncology|February 18, 2014
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastasesPaola Queirolo, Francesco Spagnolo, Paolo Antonio Ascierto, et al.
Oncology Letters|April 14, 2016
Sun exposure and melanoma prognostic factorsSara Gandini, Maurizio Montella, Fabrizio Ayala, et al.
The Oncologist|December 21, 2023
Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?Salvatore Alfieri, Rebecca Romanò, Sara Marceglia, et al.
Cancer Treatment and Research Communications|September 1, 2024
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patientsFrancesca Parisi, Giuseppa De Luca, Manuela Mosconi, et al.
Cancers|February 3, 2021
No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) StudyMichele Guida, Nicola Bartolomeo, Pietro Quaglino, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinomaAlice Baggi, Pietro Quaglino, Marco Rubatto, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2023
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profilePaolo A Ascierto, Anna M Di Giacomo, Vanna Chiarion Sileni, et al.
Pageof 12

Showing results (81-90 of 116) with videos related to

Sort By:
Pageof 12
The Lancet. Oncology|July 17, 2023
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 studyReinhard Dummer, Paola Queirolo, Pauline Gerard Duhard, et al.
The Lancet. Oncology|August 8, 2022
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 studyReinhard Dummer, Paola Queirolo, Ana Maria Abajo Guijarro, et al.
International Journal of Molecular Sciences|March 11, 2023
Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World SettingIrene Vanni, Lorenza Pastorino, Enrica Teresa Tanda, et al.
Journal of Neuro-Oncology|February 18, 2014
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastasesPaola Queirolo, Francesco Spagnolo, Paolo Antonio Ascierto, et al.
Oncology Letters|April 14, 2016
Sun exposure and melanoma prognostic factorsSara Gandini, Maurizio Montella, Fabrizio Ayala, et al.
The Oncologist|December 21, 2023
Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?Salvatore Alfieri, Rebecca Romanò, Sara Marceglia, et al.
Cancer Treatment and Research Communications|September 1, 2024
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patientsFrancesca Parisi, Giuseppa De Luca, Manuela Mosconi, et al.
Cancers|February 3, 2021
No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) StudyMichele Guida, Nicola Bartolomeo, Pietro Quaglino, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinomaAlice Baggi, Pietro Quaglino, Marco Rubatto, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2023
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profilePaolo A Ascierto, Anna M Di Giacomo, Vanna Chiarion Sileni, et al.
Pageof 12